Dr Hugo Ford
Position: Clinical Consultant
Personal home page:
PubMed journal articles - click here
My research is based on improving outcomes of chemotherapy in oesophageal and gastric cancer. I am chief investigator of a national phase 3 trial of gastric cancer chemotherapy and locally am collaborating with Rebecca Fitzgerald and Duncan Jodrell on molecular and pharmacokinetic studies of new agents in early oesophago-gastric cancer, and defining molecular determinants of response and prognosis
Ford HER, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J et al (2013): Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol published online first doi.1016/S1470-2045(13)70549-7 Strong S, Blencowe NS, Fox T, Reid C, Crosby T, Ford HER and Blazeby JM (2012): The role of Multidisciplinary teams in decision making for patients with recurrent malignant disease. Palliative Med 26(7) 954-8 Rollins KE, Peters CJ, Safranek PM, Ford HER, Baglin TP, Hardwick RH (2011) Venous thromboembolism in oesophago-gastric carcinoma: Incidence of symptomatic and asymptomatic events following chemotherapy and surgery, Eur J Surg Oncol 37(12) 1072-7 Crinò L, Zatloukal P, Reck M, Pesek M, Thompson JC, Ford HER, Hirsch FR, Varella-Garcia M et al (2008), Gefitinib Versus Vinorelbine in Chemonaïve Elderly Patients With Advanced Non-Small-Cell Lung Cancer (INVITE): A Randomized Phase II Study, J Clin Oncol 26(26):4253-60 Farrugia DC, Ford HER, Danenberg K, Cunningham D, Danenberg PV et al (2003), Thymidylate Synthase expression in advanced colorectal cancer predicts for response to raltitrexed, Clin Cancer Res 9, 792-801
